Rossell Techsys Ltd. Receives Outstanding Supplier Recognition from Lockheed Martin at the 10th Lockheed Martin Suppliers Conference
BANGALORE, India, Dec. 10, 2024 /PRNewswire/ -- Rossell Techsys Ltd. (ROSSTECH), a leading…
VLSID 2025 returns to Bengaluru to redefine innovation, from 4-8 January 2025
The World's Premier VLSI and Semiconductor Conference to focus on the convergence…
VLSID 2025 returns to Bengaluru to redefine innovation, from 4-8 January 2025
The World's Premier VLSI and Semiconductor Conference to focus on the convergence…
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT…
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivatat ASH 2024 and Provides Regulatory Update on Mitapivat
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult…
Blokees’ Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
SHANGHAI, Dec. 7, 2024 /PRNewswire/ -- During the two-day 2024 Singapore Comic…
Blokees’ Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
SHANGHAI, Dec. 7, 2024 /PRNewswire/ -- During the two-day 2024 Singapore Comic…
Blokees’ Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
SHANGHAI, Dec. 7, 2024 /PRNewswire/ -- During the two-day 2024 Singapore Comic…
Blokees’ Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
SHANGHAI, Dec. 7, 2024 /PRNewswire/ -- During the two-day 2024 Singapore Comic…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…